Overview

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart failure (CHF) patients hospitalized for an episode of acute decompensated heart failure.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals